Emergent Biosolutions
EBS
238 hedge funds and large institutions have $1.88B invested in Emergent Biosolutions in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 11 closing their positions.
373% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 11
73% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 60
25% more capital invested
Capital invested by funds: $1.5B → $1.88B (+$378M)
20% more funds holding
Funds holding: 198 → 238 (+40)
7.58% more ownership
Funds ownership: 90% → 97.58% (+7.6%)
47% less call options, than puts
Call options by funds: $684K | Put options by funds: $1.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$24.3M |
| 2 |
Renaissance Technologies
New York
|
+$18.2M |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$14.9M |
| 4 |
O
OppenheimerFunds
New York
|
+$13.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$22.3M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$11.2M |
| 3 |
Charles Schwab
San Francisco,
California
|
-$6.03M |
| 4 |
GAM
Gotham Asset Management
New York
|
-$4.93M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.85M |
EBS Hedge Fund Activity: Q4 2017 in Review
238 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2017, worth a combined $1.88B — up 25% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new EBS positions and 11 closed out — a net gain of 41 holders — while 104 added to existing stakes and 60 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $24.3M. The largest seller was Glenmede Trust, cutting an estimated $22.3M.
- 238 institutional investors held Emergent Biosolutions (EBS) as of Q4 2017, up from 198 in Q3 2017.
- Funds reported $1.88B of Emergent Biosolutions stock for Q4 2017, up 25% quarter-over-quarter.
- 52 funds opened new Emergent Biosolutions positions in Q4 2017 and 11 closed out, a net change of +41 holders.
- The largest Emergent Biosolutions buyer in Q4 2017 was Goldman Sachs, an estimated $24.3M added.
- The largest Emergent Biosolutions seller in Q4 2017 was Glenmede Trust, an estimated $22.3M sold.
Based on aggregated 13F filings for Q4 2017.